MedTrace Logo

Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)

NCT02394782 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2016-04-25

No results posted yet for this study

Summary

This is a 24-month, observational, prospective, multinational, multicenter study to determine the relationship between the relapse (percentage of relapse free subjects) and adherence in subjects diagnosed with RRMS treated with Rebif (interferon beta-1a) using the RebiSmart®2.0 and MSdialog™.

Conditions

  • Multiple Sclerosis, Relapsing-remitting

Interventions

DEVICE

RebiSmart®2.0

Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.

DEVICE

MSdialog™

Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.

Sponsors & Collaborators

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Responsible · Merck KGaA, Darmstadt, Germany

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-11-30
Completion
2016-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02394782 on ClinicalTrials.gov